Resolution of galactomannan antigenemia in a patient receiving oral voriconazole for chronic necrotizing pulmonary aspergillosis.
The serologic markers of the therapeutic response of chronic necrotizing pulmonary aspergillosis (CNPA) are rarely reported. Here, we describe the changes in galactomannan (GM) antigenemia in a patient receiving oral voriconazole for CNPA, in whom a resolution of GM antigenemia to a normal level was associated with clinical improvements. The serum GM index can be an adjunctive tool for the diagnosis and monitoring of the therapeutic response of CNPA.